{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:34:40Z","timestamp":1789907680746,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17K18213"],"award-info":[{"award-number":["17K18213"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","joms.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.joms.2018.11.016","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T12:33:58Z","timestamp":1543235638000},"page":"555.e1-555.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Remarkable Short-Term Regression of a Posterior Mediastinum Metastasis From Primary Intraosseous Carcinoma Treated With Nivolumab: A Case Report"],"prefix":"10.1016","volume":"77","author":[{"given":"Masashi","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joms.2018.11.016_bib1","series-title":"WHO Classification of Head and Neck Tumours","author":"El-Naggar","year":"2017"},{"key":"10.1016\/j.joms.2018.11.016_bib2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/0973-029X.203777","article-title":"Primary intraosseous odontogenic squamous cell carcinoma of the mandible","volume":"21","author":"Cariati","year":"2017","journal-title":"J Oral Maxillofac Pathol"},{"key":"10.1016\/j.joms.2018.11.016_bib4","doi-asserted-by":"crossref","first-page":"e0153646","DOI":"10.1371\/journal.pone.0153646","article-title":"Prognostic factors of primary intraosseous squamous cell carcinoma (PIOSCC): A retrospective review","volume":"11","author":"Wenguang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.joms.2018.11.016_bib5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cam4.106","article-title":"PD-1 as a potential target in cancer therapy","volume":"2","author":"McDermott","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.joms.2018.11.016_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.joms.2018.11.016_bib7","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2018.11.016_bib8","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2018.11.016_bib9","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In\u00a0vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in\u00a0vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.joms.2018.11.016_bib10","first-page":"596","article-title":"Nivolumab for squamous-cell cancer of head and neck","volume":"376","author":"Ferris","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2018.11.016_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.2009.23.0425","article-title":"Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial","volume":"28","author":"Kies","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2018.11.016_bib12","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1016\/j.joms.2016.05.006","article-title":"Clinicopathological study of primary intraosseous squamous cell carcinoma of the jaw and a review of the literature","volume":"74","author":"Naruse","year":"2016","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2018.11.016_bib13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1600-0714.2011.01058.x","article-title":"Primary intraosseous squamous cell carcinoma arising in an odontogenic cyst: A clinicopathologic analysis of 116 reported cases","volume":"40","author":"Bodner","year":"2011","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.joms.2018.11.016_bib14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.5858\/133.11.1834","article-title":"Primary intraosseous squamous cell carcinoma of the jaws. Clinicopathologic presentation and prognostic factors","volume":"133","author":"Huang","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.joms.2018.11.016_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1054\/ijom.2001.0069","article-title":"Primary intraosseous carcinoma of the jaw: Pooled analysis of world literature and report of two new cases","volume":"30","author":"Thomas","year":"2001","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2018.11.016_bib16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/hed.22922","article-title":"Intraosseous carcinoma of the jaws: A clinicopathologic review. Part III: Primary intraosseous squamous cell carcinoma","volume":"35","author":"Woolgar","year":"2013","journal-title":"Head Neck"},{"key":"10.1016\/j.joms.2018.11.016_bib17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jjco\/hyx097","article-title":"Prognostic importance of pathological response to neoadjuvant chemotherapy followed by definitive surgery in advanced oral squamous cell carcinoma","volume":"47","author":"Hirakawa","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.joms.2018.11.016_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/0971-5851.166716","article-title":"Neoadjuvant chemotherapy in oral cancers: Selecting the right patients","volume":"36","author":"Vishak","year":"2015","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.joms.2018.11.016_bib19","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.2012.43.8820","article-title":"Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma","volume":"31","author":"Zhong","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2018.11.016_bib20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ijom.2018.01.004","article-title":"Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma","volume":"47","author":"Maruse","year":"2018","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2018.11.016_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","article-title":"Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"112","author":"Schvartsman","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.joms.2018.11.016_bib22","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2018.11.016_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.oraloncology.2017.07.023","article-title":"A randomized, open-label, phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141","volume":"73","author":"Kiyota","year":"2017","journal-title":"Oral Oncol"}],"container-title":["Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239118312825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239118312825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:56:49Z","timestamp":1759510609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278239118312825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0278239118312825"],"URL":"https:\/\/doi.org\/10.1016\/j.joms.2018.11.016","relation":{},"ISSN":["0278-2391"],"issn-type":[{"value":"0278-2391","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remarkable Short-Term Regression of a Posterior Mediastinum Metastasis From Primary Intraosseous Carcinoma Treated With Nivolumab: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joms.2018.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Association of Oral and Maxillofacial Surgeons","name":"copyright","label":"Copyright"}]}}